Potential options for managing LOX+ ER- breast cancer patients

about

Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines.Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.

P2860

Q41660477-6231261D-97CF-4F67-BCEB-33799FAFE7A4 Q50218607-2777F1B5-32E5-401B-973E-60AA70883B85

P2860

Potential options for managing LOX+ ER- breast cancer patients

Item

http://www.wikidata.org/entity/Q37362796

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potential options for managing LOX+ ER- breast cancer patients

@en

Potential options for managing LOX+ ER- breast cancer patients.

@nl

type

Item

label

Potential options for managing LOX+ ER- breast cancer patients

@en

Potential options for managing LOX+ ER- breast cancer patients.

@nl

prefLabel

Potential options for managing LOX+ ER- breast cancer patients

@en

Potential options for managing LOX+ ER- breast cancer patients.

@nl

P1476

Potential options for managing LOX+ ER- breast cancer patients

@en

P2093

Balázs Győrffy

http://www.w3.org/2001/XMLSchema#string

Dongsheng Huang

http://www.w3.org/2001/XMLSchema#string

Kexin Meng

http://www.w3.org/2001/XMLSchema#string

Shenyi Lian

http://www.w3.org/2001/XMLSchema#string

Tao Jin

http://www.w3.org/2001/XMLSchema#string

Xingran Cui

http://www.w3.org/2001/XMLSchema#string

Yong Han

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

PARP inhibitors in the management of breast cancer: current data and future prospects

Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture

Text mining effectively scores and ranks the literature for improving chemical-gene-disease curation at the comparative toxicogenomics database

Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Col1A1 production and apoptotic resistance in TGF-β1-induced epithelial-to-mesenchymal transition-like phenotype of 603B cells.

P304

32893-32901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9073

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27147578

http://www.w3.org/2001/XMLSchema#string

P932

5078060

http://www.w3.org/2001/XMLSchema#string

Potential options for managing LOX+ ER- breast cancer patients

about

P2860

P2860

Potential options for managing LOX+ ER- breast cancer patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932